White Paper

Targeting Age-Related Macular Degeneration With Stem Cell Therapy

Source: bio-techne
Close up on eyes GettyImages-1207244495

Age-related macular degeneration (AMD), a common eye disorder leading to permanent loss of central vision, is the leading cause of blindness in developed countries. Current treatments for AMD are often ineffective, particularly for dry AMD, the most common form of the disorder. Cell therapy technologies offer potential new treatments for AMD, however, the efficacy of such treatments depends on the ability to deliver therapeutic cells to the target region and to produce enough RPE cells. On the back of the success of Induced pluripotent stem cell (iPSC) technology, a novel stem-cell therapy based upon iPSC-derived RPE cell transplantation was conceptualized as a promising new treatment for AMD and other retinal diseases. Bio-Techne aims to offer a range of animal-free cell culture products and GMP proteins for clinical manufacturing, which may boost the success of cell therapies. iPSC-based cell therapy is seen as a promising solution for AMD patients unresponsive to traditional treatments.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online